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Abstract
The present study evaluated the effect of non-absorbable oral poly-
myxin on the duodenal microflora and clinical outcome of infants
with severe infectious diarrhea. Polymyxin was chosen because clas-
sic enteropathogenic Escherichia coli was more sensitive to this
antibiotic. Twenty-five infants were randomly assigned to a 7-day
treatment with oral polymyxin (2.5 mg/kg in 4 daily doses) or placebo.
Duodenal and stool cultures were performed before and after the
treatment. Five patients were excluded during the study because of
introduction of parental antibiotic therapy due to clinical sepsis (N =
3) or rapid clinical improvement (N = 2). In the polymyxin group,
small bowel bacterial overgrowth occurred in 61.5% of the cases (8/
13) before treatment and in 76.9% (10/13) after treatment. In the
placebo group these values were 71.4% (5/7) and 57.1% (4/7), respec-
tively. By the 7th day, clinical cure was observed in 84.6% of the cases
(11/13) in the polymyxin group and in 71.4% (5/7) in the placebo
group (P = 0.587). Considering all 25 patients included in the study,
clinical cure occurred on the 7th day in 12/14 cases (85.7%) in the
polymyxin group and 6/11 cases (54.5%) in the placebo group (P =
0.102). Clinical sepsis occurred in 3/11 (27.3%) of the patients in the
placebo group and in none (0/14) in the polymyxin group (P = 0.071).
Oral polymyxin was not effective in reducing bacterial overgrowth or
in improving the clinical outcome of infants hospitalized with severe
infectious diarrhea. Taking into account the small sample size, the rate
of cure on the 7th day and the rate of clinical sepsis, further studies
with greater number of patients are necessary to evaluate these ques-
tions.
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Introduction
Diarrhea raises the levels of infant mortal-
ity and is a serious public health problem,
though mainly in developing countries. Al-
though oral rehydration therapy significantly
reduces the mortality rate of acute diarrhea
(1), persistent diarrhea has become increas-
ingly responsible for deaths, especially in in-
fants (2). Victora et al. (3) in Pelotas, RS,
Brazil, demonstrated that half of the infants
who died from persistent diarrhea were admit-
ted to hospitals during the acute phase of the
disease, showing that studies evaluating new
therapeutic modalities for hospitalized chil-
dren with severe diarrhea are necessary.
Enteropathogens such as enteroadherent
Escherichia coli, classic enteropathogenic
E. coli (EPEC), and Cryptosporidium and
Klebsiella spp have been frequently isolated
from stool samples of children with persist-
ent diarrhea (4). In São Paulo city and in
other urban centers of Brazil, EPEC has
been characterized as the main bacterial agent
in cases of acute and persistent diarrhea in
children, particularly in infants belonging to
low income families (5-10). The mechan-
isms by which these agents associate with
persistent diarrhea are not fully understood,
though they are perhaps related to the ability
of these agents to adhere to and/or invade the
intestinal mucosa (1). The events that per-
petuate the diarrheal process probably in-
clude lesions of the intestinal mucosa, intol-
erance to disaccharides and proteins in the
diet and overgrowth of bacteria of the fecal
flora in the small intestine. EPEC is also
associated with bacterial overgrowth in the
small intestine (11).
At present, it is well established that the
basis for the treatment of acute diarrhea
involves the replacement of electrolytes and
proper nutritional support (12). However,
the use of antimicrobial agents may poten-
tially have favorable effects on the elimina-
tion of enteropathogenic agents and, conse-
quently, on the cure of diarrhea. For ex-
ample, an expert group has recommended
the use of antimicrobial therapy in selected
circumstances such as EPEC diarrhea with a
prolonged course (13). However, few well-
controlled studies have evaluated the effect
of antibiotics on the treatment of these pa-
tients (12,14-16). Studies employing gen-
tamicin to treat children with persistent diar-
rhea have reported conflicting results (14-
16). Alam et al. (12) demonstrated that the
trimethoprim-sulfamethoxazole combination
reduced the duration of diarrhea and the
number of hospital infections in infants hos-
pitalized with persistent diarrhea.
The present study evaluated the effect of
a non-absorbable oral antibiotic on the duode-
nal microflora and on the clinical outcome
of infants hospitalized with severe infec-
tious diarrhea for at least 7 days.
Patients, Material and Methods
This 7-day randomized double-blind
study focused on clinical characteristics,
nutritional evaluation, and analysis of duode-
nal and stool cultures before and after the
administration of polymyxin or a placebo, in
infants hospitalized with severe infectious
diarrhea.
Medication under study
Polymyxin was chosen because it is a
non-absorbable antibiotic that affects pri-
marily the intestinal lumen (17), acting
mainly on enterobacteria, but also moder-
ately against anaerobes (18). The fact that in
São Paulo city EPEC is more sensitive to
polymyxin than other antibiotics (6) was
also taken into consideration. Polymyxin B
sulfate was used at the dose of 2.5 mg/kg,
which corresponds to 25,000 IU kg-1 dose-1
in 4 daily oral doses.
Sample size
The statistical power and significance
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level were 80% and 0.05, respectively. By
the 4th day of treatment, a 0.85% cure rate
was expected for the treated group and a rate
of 0.30% for the control group. A modified
Rosner (19) formula was used and a number
of 10 cases per group were calculated, yield-
ing a total of 20 patients. To provide a mar-
gin for error, 30 treatments were prepared
and randomized.
Treatment allocation
Polymyxin and placebo were supplied
and randomized by the Zambom Laboratory
(São Paulo, SP, Brazil). The bottles of both
treatment groups looked identical and were
sequentially numbered to correspond to the
patients’ serial numbers and randomization
code. Only the statistician, who had no con-
tact with the patients, kept a list with the
contents of each numbered vial. The placebo
had the same physical, chemical and flavor
characteristics as the antibiotic. The identity
of the treatment (polymyxin or placebo) was
unknown to the investigators until the time
of analysis.
Patients and study design
The period of data collection was from
January 1993 to April 1997. The inclusion
criterion was diarrhea for at least 7 days in
infants with less than one year of age who
needed hospitalization. Diarrhea was defined
as 3 or more liquid evacuations in the 24 h
preceding the beginning of treatment (20).
Exclusion criteria were: 1) infants with asso-
ciated disorders; 2) use of antibiotic(s) in the
7 days preceding the study; 3) patients who
did not complete the study protocol (7 days
of analysis and duodenal and stool culture
collection). Patients who presented evidence
of systemic infectious during the study pro-
tocol were also excluded from the final anal-
ysis, which included duodenal and stool cul-
tures before and after medication. However,
considering the principle of intention to treat,
the total number of patients who entered the
study were included only in the analysis of
clinical evolution to sepsis and clinical cure
on the 4th and 7th days of treatment.
The study was conducted in the Pediatric
Gastroenterology Inpatient Care Unit of the
Hospital of São Paulo, Escola Paulista de
Medicina, Universidade Federal de São Paulo
(UNIFESP-EPM). The source of patients
was the Pediatric Emergency room visits
where they received fluid and electrolyte
replacement therapy for the correction of
metabolic disorders. The hospitalization of
these patients was necessary to maintain
parenteral hydration and/or due to food in-
tolerance. Upon admission the patients were
evaluated for the presence of metabolic and
hydroelectrolytic disturbances and food in-
tolerance during their stay in the Pediatric
Emergency room visits. Food intolerance
was defined as the presence of anorexia,
vomiting, abdominal distention and/or per-
sistent diarrhea and weight loss (with an
adequate caloric supply) associated with fe-
cal pH <6.0 and/or the presence of reducing
substances in the stools (21). Patient histo-
ries were taken for data such as birth weight
and feeding history. Percentiles and Z scores
for weight/age, weight/height and height/
age were calculated using the Epi-Info pro-
gram, version 6.0 (22), related to the Na-
tional Center for Health Statistics (23) table
for weight and height.
After admission to the study, the patients
were randomly assigned to one of the two
treatment groups: one group received poly-
myxin and the other received a placebo.
The clinical course of these patients was
analyzed for 7 days (study period) and was
based on the following parameters: daily
weight gain, disappearance of diarrhea, calo-
ries received (orally or parenterally), and Z
scores for weight/age at the beginning and at
the end of the study. For the 7 days of the
study, the patients received a semi-elemen-
tal formula consisting of hydrolyzed protein
from cow milk whey, mid-chain triglyceri-
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des, cow milk fat, corn oil, maltose-dextrin,
starch, vitamins, and mineral salts. This for-
mula is equivalent to 220 mOsm/L and 72
kcal/dL (Alfaré, Nestlé®, Lousanne, Swit-
zerland).
On the basis of World Health Organiza-
tion recommendations (2), a clinical cure
was defined as the disappearance of diarrhea
and the attainment of a weight higher than
the one observed at the beginning of the
study (2). The proportion rate of clinical
cure was evaluated on the 4th and 7th days
of treatment.
Laboratory evaluation before and after 7
days on medication or placebo, included
stool cultures (24), duodenal secretion cul-
tures with tests for aerobic (24) and anaero-
bic (25) bacteria, and a susceptibility test for
antibiotics, including polymyxin for aerobic
bacteria (26). Upon admission to the study,
tests were performed for rotavirus in stool
(27), Giardia lamblia, Entamoeba histolyti-
ca (28) and Cryptosporidium in stool (29),
and G. lamblia trophozoites using freshly
obtained duodenal fluid (30). Small bowel
bacterial overgrowth (SBBO) was charac-
terized by the presence of any number of
aerobic or anaerobic microorganisms com-
mon to the flora of the colon, determined by
the isolation of a fluid culture from the je-
junum (31,32). In the cases that presented
bacterial proliferation in the small intestine
before treatment, a bacteriological cure was
defined as the disappearance of bacterial
proliferation in the small intestine by the end
of treatment, i.e., after 7 days of medication.
Transitory flora, nasopharynx and respira-
tory tract bacteria were not taken into con-
sideration.
Laboratory tests
Stool. E. coli strains were isolated on
MacConkey agar. Four separate lactose-fer-
menting colonies, presumed to be E. coli by
colony morphology, and two non-lactose-
fermenting colonies of each distinct mor-
phologic type were cultivated in EPM and
MILi (33) media for biochemical confirma-
tion of the species or genus. All E. coli
colonies were submitted to slide agglutina-
tion with polyvalent and monovalent anti-
sera (PROBAC do Brasil, São Paulo, SP,
Brazil) against O antigens of EPEC sero-
groups and enterohemorrhagic E. coli. The
serogroups considered were as follows: O26,
O55, O86, O111, O119, O125, O126, O127,
O128ab, O142, O157, and O158. Shigella
spp, Salmonella spp, Yersinia spp were tested
by standard methods (24). Rotavirus (27),
G. lamblia, E. histolytica (28), and Crypto-
sporidium (29) were all tested.
Duodenal fluid
A sterile enteral probe (Peditube®, Bio-
search Medical Products, Inc., Somerville,
NJ, USA) was used to collect duodenal
samples. The procedure was always per-
formed in a sterile surgical environment.
The collection of duodenal secretions was
carried out after a fast of at least 4 h (34)
using a previously described technique (35)
which facilitates the manual progression of
the probe to the duodenum using a special
guide wire. The probe was considered to
have reached the duodenum when an aspi-
rate of yellowish digestive fluid of a pH
higher than 6.0 was encountered. The first
milliliter aspirated was discarded due to the
possibility of probe contamination with oro-
pharyngeal or stomach secretions (34). A
0.5-mL sample was then aspirated into a
sterile syringe for the culture of aerobic mi-
crobes, another 0.5-mL sample, free of air
bubbles, was obtained, for the culture of
anaerobes and a final 0.5-mL sample was
obtained to test for G. lamblia trophozoites,
the fresh liquid being examined with a light
microscope (30). The samples were quickly
transported to the laboratory for immediate
processing. The time spent carrying out the
procedures was recorded for all samples.
For the anaerobe tests 0.5-mL duodenal as-
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pirate samples, free of air bubbles, were
processed for culture and identification of
anaerobic bacteria (25). A colony count per
milliliter was performed using a colony col-
lection plate that had a greater dilution of
collected material. For the aerobe tests 0.5-
mL duodenal aspirate samples were pro-
cessed for the culture and identification of
Gram-positive aerobic cocci and Gram-nega-
tive aerobic bacteria (24) and colonies were
counted by the same procedure as used for
the anaerobes. Using the disk diffusion
method, the aerobic pathogens isolated from
the duodenal secretions were tested for sus-
ceptibility to antibiotics, including polymyxin
(26).
Statistical analysis
The Student t-test, the Mann-Whitney
test, and the one-tailed Fisher exact test were
used to compare the variables for the two
independent groups.
The calculations were performed using
the Epi-Info program, version 6.0 (22) and
the Jandel Sigma-Stat (36) program.
Ethical considerations
The project was approved by the Ethics
Committee of the Hospital of São Paulo
(UNIFESP-EPM) and informed written con-
sent was obtained from the persons respon-
sible for the infants.
Results
Initially, 25 patients were included con-
secutively in the study, but subsequently 5
of them had to be excluded during the study
period for the following reasons: introduc-
tion of parenteral antibiotic therapy (N = 3)
due to clinical sepsis and clinical improve-
ment (N = 2).
At the time of analysis, the opening of the
double-blind trial seal revealed that the three
patients who presented sepsis had received
placebo and of the two patients who pre-
sented clinical improvement, one received
placebo and the other polymyxin. There were
no adverse effects due to the drug employed.
Thus, 20 patients completed treatment, 13 of
them receiving polymyxin and 7 placebo.
None of the patients died. Comparing the 5
patients excluded with the 20 patients who
completed the study, there were no statitical
significant differences between clinical and
laboratorial data (data not shown).
Upon admission, both groups presented
similar clinical and laboratory characteris-
tics, as shown in Table 1. All patients
(100.0%) presented food intolerance, 80.0%
had “severe dehydration” and the majority
presented metabolic acidosis and electrolyte
imbalances, clear evidence that these pa-
tients presented a severe episode of diarrhea.
Table 2 shows the results of the aspirated
duodenal cultures and of the stool cultures
for the groups studied. If we consider all the
patients admitted to the study, the isolation
Table 1. Characteristics of patients upon admission to the study.
Polymyxin (N = 14) Placebo (N = 11)
Age (months)1 4.64 ± 1.86 3.24 ± 1.97
Gender (male/female)3 9/5 8/3
Duration of diarrhea (days)2 13 (7-21) 14 (9-18)
Birth weight (g)1 2898 ± 688 2987 ± 639
Weaned (<3 months)3 13 (92.8%) 11 (100%)
Z score for weight/age1 -2.0 ± 1.1 -1.6 ± 1.2
Z score for height/age1 -1.8 ± 1.3 -2.0 ± 1.4
Z score for weight/height1 -0.9 ± 1.0 -0.3 ± 0.4
Moderate dehydration3 2 (14.3%) 3 (27.3%)
Severe dehydration3 12 (85.7%) 8 (72.7%)
Feeding intolerance3 14 (100%) 11 (100%)
Metabolic acidosis (pH <7.35)3 10 (71.4%) 8 (72.7%)
Electrolyte imbalance3 8 (57.1%) 5 (45.4%)
Hemoglobin (g/dL)1 8.7 ± 1.4 8.8 ± 2.1
SBBO3 8 (57.1%) 9 (81.8%)
Stool culture positive for enteropathogens3 9 (64.3%) 7 (63.6%)
EPEC (stools)3 7 (50.0%) 7 (63.6%)
Data are reported as mean ± SD, number of patients with percent in parentheses or as
indicated in Table. Electrolytic imbalances considered were: hyponatremia (Na+ <130
mEq/L), hypocalcemia (K+ <3.5 mEq/L), or hypercalcemia (K+ >6.0 mEq/L). SBBO =
small bowel bacterial overgrowth; EPEC = classic enteropathogenic Escherichia coli.
P > 0.05 for comparisons of all parameters between the polymyxin and placebo
groups (1Student t-test, 2Mann-Whitney test, 3Fisher test).
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Table 2. Cultures of stools and duodenal secretion obtained from the patients upon admission and at the end of the study.
Group    Feces Duodenal secretion
(Patient No.)
Initial Final Initial SBBO Final SBBO
Polymyxin
1 EPEC O111 - EPEC O111 109 Y Enterococcus spp 107 Y
Klebsiella spp 105
2 - - Enterococcus spp 102 Y Enterococcus spp 103 Y
S. aureus 101
S. viridans 101
5 EPEC O111 - EPEC O111 109 Y Nonpathogenic E. coli 103 Y
Peptococcus spp 103
6 - - Enterobacter spp 103 Y Enterobacter spp 103 Y
Nonpathogenic E. coli 103 S. aureus 103
S. viridans 103
7 EPEC O111 - EPEC O111 107 Yeast 104 Y Yeast 107 N
10 EPEC O55 - EPEC O26 106 Y Proteus morgani 104 Y
Proteus morgani 104
Klebsiella pneumoniae 104
13 Shiguella sonnei - S. viridans 104 N S. viridans 104 Y
Bifidobacterium spp 105
14 EPEC O111 - Nonpathogenic E. coli 102 Y Nonpathogenic E. coli 102 Y
P. aeruginosa 102
15 EPEC O119 - S. aureus 102 N S. maltophilia 104 Y
16 - - Yeast 101 N S. maltophilia 104 Y
17 EPEC O119 - Nonpathogenic E. coli 103 Y Nonpathogenic E. coli 102 Y
P. aeruginosa 102 P. aeruginosa 102
Bifidobacterium spp 102
Peptococcus spp 102
18 - - S. aureus 103 N S. aureus 103 N
S. ß hemolytic G 103 S. ß hemolytic G 103
19 Shiguella flexneri -                - N             - N
23 - NP Propionibacterium spp 104 N                 NP NP
Placebo
3 - - Nonpathogenic E. coli 101 Y Nonpathogenic E. coli 103 Y
Klebsiella spp 103
4 - - Nonpathogenic E. coli 107 Y S. aureus 105 N
S. aureus 107
8 EPEC O111 - Yeast 101 N S. aureus 102 N
9 EPEC O119 - EPEC O119 105 Y Nonpathogenic E. coli 103 Y
S. aureus 103
11 - EPEC O111                - N Nonpathogenic E. coli 104 Y
12 EPEC O111 - EPEC O111 104 Y EPEC O111 104 Y
20 EPEC O127 - K. pneumoniae 107 Y S. epidermidis 106 N
K. oxytoca 104
21 - NP Pseudomonas spp 102 Y                 NP NP
S. epidermidis 105
22 EPEC O111 NP EPEC O111 105 Y                 NP NP
24 EPEC O55 NP EPEC O55 105 Y                 NP NP
Enterobacter spp 106
25 EPEC O111 NP K. pneumoniae 109 Y                 NP NP
SBBO = small bowel bacterial overgrowth; EPEC = classic enteropathogenic Escherichia coli; S. aureus = Staphylococcus aureus; S. viridans =
Streptococcus viridans ; P. aeruginosa = Pseudomonas aeruginosa; S. maltophilia = Strenotophomonas maltophilia; S. ß hemolytic G =
Streptococcus ß hemolytic G. Anaerobes in bold print. The duodenal secretion culture result is reported as number of colonies (org/mL). SBBO
occurred in 31 of 45 samples of duodenal secretion (Y = Yes, N = No, NP = not performed).
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of an enteropathogenic agent from the stool
cultures was 64.0% (16/25) at the beginning,
with EPEC being the main pathogen found,
occurring in 56.0% of cases (14/25), fol-
lowed by Shigella in 8.0% of cases (2/25).
At the end of the study, stool cultures were
positive in 5.0% (1/20) of cases, and EPEC
was isolated from one patient from the pla-
cebo group. The following EPEC serogroups
were isolated from stool samples and are
listed in decreasing order of frequency: O111
(N = 8), O119 (N = 3), O55 (N = 2), and
O127 (N = 1). Rotavirus, Cryptosporidium,
E. histolytica, and G. lamblia were not found
in any patient.
The aspirated duodenal cultures were
positive in 93.3% of the samples (42/45),
with aerobic microorganisms in 84.4% (38/
45) and anaerobic microorganisms in 8.9%
(4/45). Transitory flora was found in 24.4%
(11/45) and was associated with coliforms in
13.3% (6/45). SBBO occurred in 68.8% (31/
45) of the samples. Among the aerobic
coliforms, E. coli was the bacterium most
commonly isolated, occurring in 20/45
(44.4%) of the samples, followed by Kleb-
siella, in 11.1% (5/45), and Enterococcus
and Enterobacter in 6.7% (3/45). EPEC was
isolated from 20.0% (9/45) of the duodenal
aspirate samples, found in 8 of the samples
at the beginning of the study and in one at the
end. The following serogroups were pres-
ent: O111 (N = 6), O119 (N = 1), O55 (N =
1), and O26 (N = 1).
The susceptibility test (by the disk diffu-
sion method) for aerobic microorganisms
revealed that all the Gram-negative bacteria
(including pathogenic and nonpathogenic E.
coli) were sensitive to polymyxin.
At the end of the study, there was no
statistical difference between the polymyxin
and placebo groups that completed the study
regarding the following parameters: average
calories received (over the 7 days), average
weight gain (over the 7 days), difference in
weight/age Z score, percentage weight gain
(over the 7 days), persistence of diarrhea (in
days during the test period of 7 days), and
clinical cure on the 4th (P = 0.651) and 7th (P
= 0.587) days of treatment (Table 3).
Table 4 shows the evolution to sepsis
during the study period and clinical cures on
the 4th and 7th days of treatment, consider-
ing all the 25 patients included in the study.
There was no statistical difference (P = 0.647)
between the polymyxin group (35.7%) and
the placebo group (36.4%) on the 4th day of
treatment. The polymyxin group presented a
higher fraction of clinical cures on the 7th
day of treatment (85.7%) than the placebo
group (54.5%), however, this difference was
not statistically significant (P = 0.102).
Among all patients included in the study, the
evolution to systemic infection (clinical sep-
sis) occurred in 3/11 (27.3%) patients in the
placebo group during the 7-day study period
and in no patient in the polymyxin group.
Table 4. Clinical course of the polymyxin and placebo groups considering the total
number of patients who entered the study.
Polymyxin (N = 14) Placebo (N = 11)
Sepsis evolution during the study period 0 (0.0%) 3 (27.3%)
Clinical cure (4th day) 5 (35.7%) 4 (36.4%)
Clinical cure (7th day) 12 (85.7%) 6 (54.5%)
Data are reported as number of patients and percent in parentheses.
P > 0.05 for comparisons between the polymyxin and placebo groups (Fisher test).
Table 3. Clinical course of the polymyxin and placebo groups that completed the
study.
   Polymyxin (N = 13) Placebo (N = 7)
Mean calories received from the 123.2 ± 36.7 128.6 ± 30.7
1st to the 7th day (kcal kg-1 day-1)1
Mean weight gain from 1st to 7th day (g)1 371.5 ± 267.3 275.7 ± 243.6
∆Z weight/age1 +0.278 ± 0.267 +0.091 ± 0.323
%∆ weight1 8.47 ± 6.15 6.06 ± 5.54
Duration of intravenous hydration (days)2 3.0 (0-5.0) 4.0 (0-6.2)
Duration of diarrhea (days)2 4.0 ± 1.87 3.8 ± 2.34
Clinical cure (4th day)3 4 (30.8%) 3 (42.8%)
Clinical cure (7th day)3 11 (84.6%) 5 (71.4%)
Data are reported as mean ± SD, number of patients with percent in parentheses or as
indicated in Table.
P > 0.05 for comparisons of all parameters between the polymyxin and placebo groups
(1Student t-test; 2Mann-Whitney test; 3Fisher test).
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Fisher’s test showed a P value equal to 0.072.
Comparative statistical analysis of the
laboratory characteristics between the poly-
myxin and placebo groups at the beginning
and the end of the study did not reveal any
significant differences regarding the follow-
ing parameters: bacterial proliferation in the
small intestine, positive stool culture, and
presence of EPEC (fecal and duodenal aspi-
rate; Table 5). The time needed for the col-
lection of duodenal aspirate was similar for
the polymyxin and placebo groups. The
median time was 30.0 min and the maximum
time was 70.0 min.
Discussion
It is well established that antimicrobial
therapy usually is not recommended for chil-
dren with diarrhea. However, antimicrobials
may be useful in reducing associated enteric
symptoms, including watery diarrhea and/or
dysentery or fever in the more severe cases
of illness and in the management of persist-
ent diarrhea (37). The studies of Bartlett et
al. (15) and Bhatnagar et al. (16), both of
them controlled, demonstrated respectively
the lack of clinical efficacy of gentamicin in
children with persistent diarrhea in the com-
munity and in hospitalized patients with mild
to moderate cases of diarrhea. Our study
confirms the lack of efficacy of antibiotics in
the treatment of diarrhea as observed in those
studies (15,16). Addionally, we analyzed
patients with severe diarrhea, most of them
in their first semester of life, characteristic
that differentiates our study from the previ-
ous ones (15,16). Bhatnagar et al. (16) stud-
ied children aged 3 months to 4 years and
Bartlett et al. (15) studied children aged 3-35
months.
It should be emphasized that exclusive
breast-feeding may decrease the risk of acute
and persistent diarrhea, since human milk
has protective properties against diarrhea
such as avoidance of exposure to bacteria,
antimicrobial agents, anti-inflammatory and
immunomodulating factors and promotion
of healthy microflora (4). Almost all (24/25,
96.0%) of our patients were weaned before 3
months of life and all of them were receiving
non-human milk on admission to the study.
This fact may have probably contributed to
severe infectious diarrhea and to the bacte-
rial overgrowth that occurred in our patients.
All of our patients presented food intol-
erance and dehydration, and most of them
presented metabolic acidosis and electrolyte
imbalances. Although infants with severe
acute diarrhea were included, all were cases
of more than 7 days of duration and required
hospitalization, thus demonstrating the per-
sistent tendency of the cases. Most episodes
of acute diarrhea resolve within 7 days and
progressively smaller proportions persist
beyond 14, 21, or 29 days. The delineation
of persistent diarrhea as a subgroup distinct
from acute diarrhea is, as such, arbitrary.
In our study, clinical sepsis and the need
for parenteral antibiotics were greater in the
placebo group (27.3%) than in the poly-
myxin group (0.0%, P = 0.07). Alam et al.
(12) also suggested that antibiotic therapy
can play a preventive role against hospital
infections, since infections occurred in 37.0%
of the placebo group and in only 3.6% of the
trimethoprim-sulfamethoxazole group (P =
0.03).
In the present study, no statistical differ-
ence was found in the percentage of cure on
Table 5. Initial and final laboratory characteristics of the polymyxin and placebo
groups.
Laboratory characteristics Polymyxin (N = 13) Placebo (N = 7)
Initial SBBO 8 (61.5%) 5 (71.4%)
Final SBBO 10 (76.9%) 4 (57.1%)
Positive initial stool culture 9 (69.2%) 4 (57.1%)
Positive final stool culture 0 (0%) 1 (14.3%)
Initial EPEC 7 (53.8%) 4 (57.1%)
Final EPEC 0 (0%) 2 (28.6%)
SBBO = small bowel bacterial overgrowth; EPEC = classic enteropathogenic Escheri-
chia coli present in the stool and in the duodenal aspirate.
P > 0.05 for comparisons of all parameters between the polymyxin and placebo groups
(Fisher test).
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the 4th day of treatment between the poly-
myxin group (30.8%) and the placebo group
(42.8%), results similar to those reported by
Bhatnagar et al. (16) and Bartlett et al. (15).
On the other hand, Alam et al. (12) reported
a higher proportion of significant therapeu-
tic success (cessation of diarrhea with 7 days
of treatment) in the trimethoprim-sulfameth-
oxazole group (82.1%) than in the placebo
group (55.5%). On the 7th day, our study
showed a cure rate of 84.6% for the poly-
myxin group and of 71.4% for the placebo
group (P = 0.58).
There was no difference in the mean
number of calories received (cal kg-1 day-1)
between the polymyxin (123.2 ± 36.7) and
placebo groups (128.6 ± 30.7). The poly-
myxin group presented a higher weight gain
(371 ± 267 g) than the placebo group (276 ±
244 g), although the difference was not sta-
tistically significant. Perhaps the patients in
the polymyxin group presented a greater
potential for recovery with the administra-
tion of nutritional therapy, since they had a
greater weight deficiency at the beginning of
the study.
Infection with EPEC is one of the main
risk factors associated with death in children
with diarrhea. When the clinical features of
diarrhea caused by EPEC are compared to
those caused by other pathogens, children
with EPEC are more likely to fail oral rehy-
dration therapy, have intolerance to cow’s
milk, require hospitalization, and develop
persistent diarrhea (38). EPEC was the main
enteropathogenic agent isolated from the fe-
ces (56.0%) of the patients admitted to our
study and in 20.0% of these cases it was also
found in the duodenal fluid. Serogroups O111
and O119 predominated, as has occurred
classically in the city of São Paulo (7). There
was no statistical difference in EPEC posi-
tivity between the placebo and polymyxin
groups at the end of the study.
In the present study, rotavirus was not
identified, probably because the population
studied was of low-socioeconomic status
and mostly aged less than 6 months.
 Since SBBO is one of the perpetuating
factors of diarrhea, most investigators con-
sider the use of antibiotics against persistent
diarrhea to be generally justified. However,
the present study was the first to carry out
duodenal secretion cultures before and after
the administration of antibiotic therapy or
placebo, analyzing the clinical and bacterio-
logical cures of the SBBO cases. Some stud-
ies in this area of research have not investi-
gated the duodenal microflora (12,14) while
others have, but only before administering
medication (15,16). In addition, the patients
who used antibiotics in the 7 days preceding
the protocol were not included in our study,
in contrast to the study by Bhatnagar et al.
(16), which included patients who had re-
ceived or not prior antibiotic therapy.
Bhatnagar et al. (16) employed qualita-
tive and quantitative criteria in the charac-
terization of SBBO. Bartlett et al. (15) em-
ployed quantitative and qualitative criteria
independent of the presence of fecal coli-
forms. We considered the presence of fecal
coliforms in the duodenal aspirate as a crite-
rion for the presence of SBBO, regardless of
the total bacterial count. Two previous stud-
ies, one of which was carried out by our
group, found a predominance of enterobac-
teria in the duodenal aspirate of children
with diarrhea, while the Gram-positive cocci
predominated in the control group (31,32). It
is worth mentioning that our patients pre-
sented shorter median intubation times (30.0
min) in relation to the maximum allowed
time (4 h), considered to be safe for the
diagnosis of SBBO (31).
E. coli was the aerobic coliform most
frequently isolated from the duodenal aspi-
rate (44.4%), similar to the findings of previ-
ous studies (31,34), followed by Klebsiella
spp (11.1%), also frequently found in other
studies (11,32). Since bacteria such as E.
coli have been frequently isolated from the
duodenal aspirate of children with persistent
diarrhea, antibiotics employed to act against
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SBBO should present a spectrum of action
for these pathogens.
Thóren et al. (39), in 1980, upon finding
significant differences in the antibiotic treat-
ment of children hospitalized with diarrhea
caused by EPEC, suggested the use of anti-
biotics chosen for local conditions. Poly-
myxin did not interfere with SBBO and it is
difficult to explain why 3 patients in the
polymyxin group presented SBBO only at
the end of the study. Besides, the spectrum
of action of polymyxin was adequate, since
all the Gram-negative bacteria, including
pathogenic and non-pathogenic E. coli, were
sensitive to this antibiotic in vitro. Further-
more, resistance to gentamicin did not ex-
plain the therapeutic failure in the studies of
Bhatnagar et al. (16) and Bartlett et al. (15),
since both reported that the isolated patho-
gens presented in vitro susceptibility to this
drug.
Considering the principle of intention to
treat and all the patients who entered the
present study, there was a greater proportion
of clinical cure on the 7th day of treatment in
the polymyxin group, but the difference was
not significant, perhaps due to our small
sample size. It is difficult to explain the
lower prevalence of clinical sepsis in the
group that received polymyxin than in the
placebo group. Perhaps this non-absorbable
antibiotic prevented bacterial translocation.
This hypothesis should be tested since chil-
dren with persistent diarrhea present almost
30 to 40% of associated systemic infections
(40). However, the role of antibiotics in this
clinical condition has not been evaluated
previously.
Taking into account the small sample
size and the rate of cure on the 7th day and
the rate of clinical sepsis, we understand that
further studies with greater sample size
should evaluate these questions. The de-
crease in the incidence of infant attended
with diarrhea in our hospital does not allow
to perform this kind of study.
In conclusion, it is important to empha-
size that, in spite of the persistence of bacte-
rial overgrowth in the small intestine, both
groups in our study presented satisfactory
clinical and weight evolution, a fact that
reinforces the importance of nutritional thera-
py in the treatment of infants hospitalized
with severe infectious diarrhea.
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